Invitae Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVTAQ research report →
About the company
Invitae Corporation (NVTAQ) operates as a medical genetics enterprise, striving to advance healthcare outcomes by furnishing crucial genetic information to individuals across the United States, Canada, and other international markets. The company's diverse offerings include genetic diagnostic services for various clinical domains, such as hereditary cancer risk assessment, targeted oncology, women's health concerns, rare medical conditions, and pharmacogenomics (the study of how genes affect a person's response to drugs). Additionally, Invitae delivers innovative digital health solutions and comprehensive health data management services.
- CEO
- Kenneth D. Knight
- IPO
- 2015
- Employees
- 1,700
- HQ
- San Francisco, CA, US
Price Chart
- Market Cap
- $85.95K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- 0.04
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
- Gross Margin
- 19.18%
- Op Margin
- -138.34%
- Net Margin
- -601.64%
- ROE
- -201.69%
- ROIC
- -37.74%
- Revenue
- $487.00M · -5.68%
- Net Income
- $0 · 100.00%
- EPS
- $0.00 · 100.00%
- Op Income
- $175.45M
- FCF YoY
- 0.00%
- 52W High
- $1.09
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.19
- Beta
- 2.80
- Avg Volume
- 240.29K
Get TickerSpark's AI analysis on NVTAQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NVTAQ coverage
Recent articles, reports, and earnings notes.
No research on NVTAQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVTAQ report →Similar companies
Peers in the same neighborhood.